Third-line Therapy for metastatic Renal cell carcinoma

被引：0
|
作者：
Rexer, H. [1 ]
机构：
[1] MeckEvidence Geschaftsstelle AUO, D-17252 Schwarz, Germany
来源：
ONKOLOGE | 2011年 / 17卷 / 12期
关键词：
D O I：
10.1007/s00761-011-2173-y
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
[No abstract available]
引用
收藏
页码：1161 / 1162
页数：2
相关论文
共 50 条
  • [21] Third-line therapy for metastatic colorectal cancer
    Gundgaard, M. G.
    Soerensen, J. B.
    Ehrnrooth, E.
    [J]. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2008, 61 (01) : 1 - 13
  • [22] Recent developments in second and third line therapy of metastatic renal cell carcinoma
    Vitale, Maria Giuseppa
    Carteni, Giacomo
    [J]. EXPERT REVIEW OF ANTICANCER THERAPY, 2016, 16 (05) : 469 - 471
  • [23] Bone metastases affect prognosis but not effectiveness of third-line targeted therapies in patients with metastatic renal cell carcinoma
    Iacovelli, Roberto
    Santini, Daniele
    Rizzo, Mimma
    Felici, Alessandra
    Santoni, Matteo
    Verzoni, Elena
    Masini, Cristina
    Massari, Francesco
    Calvani, Nicola
    Mosca, Alessandra
    Procopio, Giuseppe
    [J]. CUAJ-CANADIAN UROLOGICAL ASSOCIATION JOURNAL, 2015, 9 (7-8): : 263 - 267
  • [24] Efficacy of treatment beyond third-line (3L) in metastatic clear-cell renal cell carcinoma (mccRCC).
    Guida, Annalisa
    Le Teuff, Gwenael
    Silva, Carolina Alveosta
    Blameble, Emeline Colomba
    Salviat, Flore
    Baciarello, Giulia
    Derosa, Lisa
    Loriot, Yohann
    Fizazi, Karim
    Di Palma, Mario
    Massard, Christophe
    Escudier, Bernard
    Albiges, Laurence
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (06)
  • [25] Targeted treatment beyond third-line in metastatic Renal Cell Carcinoma (mRCC): Single center outcome of 22 patients
    Vallet, S.
    Hoefner, T.
    Pahernik, S.
    Tosev, G.
    Hadaschik, B.
    Duensing, S.
    Hohenfellner, M.
    Jaeger, D.
    Gruellich, C.
    [J]. ONCOLOGY RESEARCH AND TREATMENT, 2014, 37 : 91 - 91
  • [26] Prognostic Factors in Patients Receiving Third Line Targeted Therapy for Metastatic Renal Cell Carcinoma
    Iacovelli, Roberto
    Farcomeni, Alessio
    Sternberg, Cora N.
    Carteni, Giacomo
    Milella, Michele
    Santoni, Matteo
    Cerbone, Linda
    Di Lorenzo, Giuseppe
    Verzoni, Elena
    Ortega, Cinzia
    Sabbatini, Roberto
    Ricotta, Riccardo
    Messina, Caterina
    Lorusso, Vito
    Atzori, Francesco
    De Vincenzo, Fabio
    Sacco, Cosimo
    Boccardo, Francesco
    Valduga, Francesco
    Massari, Francesco
    Baldazzi, Valentina
    Cinieri, Saverio
    Mosca, Alessandra
    Ruggeri, Enzo Maria
    Berruti, Alfredo
    Procopio, Giuseppe
    [J]. JOURNAL OF UROLOGY, 2015, 193 (06): : 1905 - 1910
  • [27] Second or Third-Line-Therapy for inoperable, locally advanced or metastatic Renal Cell Carcinoma
    Rexer, H.
    Retz, M.
    Steiner, T.
    [J]. UROLOGE, 2021, 60 (06): : 836 - 837
  • [28] Application of the Meet-URO score to metastatic renal cell carcinoma patients treated with second- and third-line cabozantinib
    Rebuzzi, Sara Elena
    Cerbone, Luigi
    Signori, Alessio
    Santoni, Matteo
    Murianni, Veronica
    De Giorgi, Ugo
    Procopio, Giuseppe
    Porta, Camillo
    Milella, Michele
    Basso, Umberto
    Massari, Francesco
    Maruzzo, Marco
    Iacovelli, Roberto
    Battelli, Nicola
    Carmisciano, Luca
    Banna, Giuseppe Luigi
    Buti, Sebastiano
    Fornarini, Giuseppe
    [J]. THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2022, 14
  • [29] Efficacy and safety of axitinib as third line therapy in metastatic renal cell carcinoma (mRCC): Retrospective analysis
    Guida, A.
    Matias, M.
    Albiges, L.
    Derosa, L.
    Loriot, Y.
    Massard, C.
    Fizazi, K.
    Escudier, B.
    [J]. EUROPEAN JOURNAL OF CANCER, 2015, 51 : S521 - S521
  • [30] Efficacy and safety of axitinib as third line therapy in metastatic renal cell carcinoma (mRCC): retrospective analysis
    Guida, A.
    Matias, M.
    Albiges, L.
    Derosa, L.
    Loriot, Y.
    Massard, C.
    Fizazi, K.
    Escudier, B.
    [J]. ANNALS OF ONCOLOGY, 2015, 26 : 60 - 60
12345